Bullous pemphigoid (BP), which has no FDA-approved targeted therapies, leads to reddening of the skin and the formation of ...

If approved, Dupixent would be the first and only targeted medicine to treat bullous pemphigoid in the ... as a chronic debilitating and relapsing skin condition, BP is driven by type 2 ...

Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application ...

This week, the European Commission granted approval to Merck’s MRK novel HIF-2α inhibitor, Welireg, for two indications. The ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been accepted for priority review by the US Food and Drug Administration (FDA ...

Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

Dupixent is a targeted medicine developed for treating bullous pemphigoid (BP), a chronic skin disease marked by intense itch and blisters. What significant results did the Dupixent trial achieve?

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...